

Sign up online at <u>www.covermymeds.health</u>. Or complete entire form and fax to Novartis Patient Support at 866-433-2300. Questions? Contact 87-RHAPSIDO (877-427-7436). An incomplete Start Form may delay the start of treatment.

Novartis Patient Support™

RHAPSIDO® (remibrutinib) START FORM

= REQUIRED

1. Patient Information Fo	or patients under 18 years of age, please	provide parent or Authorized Representative's email and phone number.
> First Name	★ Last Name	Phone Number — We'll keep you informed through non-marketing calls and texts. → Phone Number — We'll keep you informed through non-marketing calls and texts.*
_		Female OK to Leave Voicemail for RHAPSIDO: Yes No
Date of Birth (MM/DD/Y)	(YY)	
★ Address (No PO Box)		Preferred Language: English Spanish Other:
* City	★ State ★ ZIP	Email
I give permission to disclose n	ny personal health information to the follo	owing Caregiver (optional):
Caregiver Name	Relationship to Patient	Caregiver Phone Number — We'll keep you informed through non-marketing calls and texts:
2. Patient Authorizati	on and Additional Enrollment Co	ensents Thave read and agree to the Patient Authorization on page 3.
X Patient/Authorized F	Representative Signature	☐ Check here if signed by an Authorized Representative.
CO-PAY PLUS† FOR RHA		·
Pay as little as \$0		ess to ongoing support. I'll get RHAPSIDO tips, resources, and reminders
I have read and agree to	from Novartis Patient Su	pport at the phone number(s) I gave.
the Co-Pay Plus Terms Conditions on page 3.	These calls and texts may be autom not a condition of getting any goods	eive recurring marketing calls and texts from and on behalf of Novartis Pharmaceuticals Corporation. attic or recorded in advance. The number of calls and message frequency may vary. My consent is s or services from Novartis. I can opt out of the program at any time by calling 87-RHAPSIDO DP" to any Novartis Patient Support Ongoing Support message to opt out of texts or "HELP" for more sage and data rates may apply.
		k) of the patient's insurance card(s) and/or complete the section below. nt Is Uninsured Image(s) of Insurance Card(s) Included ntage Medicare Part D Medicaid Other:
★ Insurance/Payer	Plan Nam	e Policy Phone Number
★ Member ID Number	x Rx Gr	roup Number
★ PCN Number	★ BIN N	umber
Primary Medical Insurance	Private Medicare Advantage	e
Insurance/Payer	Plan N	Jame Policy Phone Number
Member ID Number	Group	o Number

DO NOT FAX PATIENT MEDICAL RECORDS. ANY MEDICAL RECORDS SHARED WILL BE DESTROYED.

To report an adverse event, call 1-888-NOW-NOVA

or visit www.novartis.com/report





Sign up online at <u>www.covermymeds.health</u>. Or complete entire form and fax to Novartis Patient Support at 866-433-2300. Questions? Contact 87-RHAPSIDO (877-427-7436). An incomplete Start Form may delay the start of treatment.

	★ Da	te of Birth (MM/DD/YYYY)	
★ Last Name	★ Pra	actice Name	
	₩ Pra	actice Phone Number	
★ State ★ ZI	Practic	e Contact Name	
	Practic	e Contact Phone Number	
	* Pra	actice Fax	
L50.8 Other (chronic, recurr	nt) urticaria 🔲 L50	0.9 Urticaria, unspecified Other	?
Dosage		Quantity	Refills
25 mg orally twice daily		60 tablets 180 tablets	11 refills, or refills
this form. I certify that any medic ssistance Foundation, Inc., and i	ation received from Nova s service providers ("NPA mbursement in any form	rtis Pharmaceuticals Corporation, its affil F"), will be used only for the patient name I acknowledge that NPAF is exclusively	iates and service providers ed on this form and will not be
	L50.8 Other (chronic, recurre erred Specialty Pharmacy int Preferred Spec Dosage 25 mg orally twice daily ly necessary and this information this form. I certify that any medica ssistance Foundation, Inc., and its ned for credit, or submitted for rei	Last Name * Practice State ZIP Practice Practice Practice	Practice Phone Number Practice Contact Name Practice Contact Phone Number Practice Fax Practice Fax L50.8 Other (chronic, recurrent) urticaria L50.9 Urticaria, unspecified Other Contact Phone Number Practice Fax Preferred Specialty Pharmacy information below: Please note: A patient's health plan may dictate as Preferred Specialty Pharmacy Phone Number Pharmacy

DO NOT FAX PATIENT MEDICAL RECORDS. ANY MEDICAL RECORDS SHARED WILL BE DESTROYED.

To report an adverse event, call 1-888-NOW-NOVA

or visit www.novartis.com/report



Novartis Patient Support

Patient Authorization. I authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation, Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for, access to, and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis copay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information.

 Communications may be customized based on Personal Information obtained from my Providers.
- Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws.

I understand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 877-427-7436 or by writing to:

Novartis Patient Support Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. For Maryland healthcare providers, this authorization expires 1 year from the date of signature. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

*Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (eg, to help you access and start on RHAPSIDO). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 877-427-436.

*Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

The Bridge Program applies to RHAPSIDO® only. Eligible patients must have private insurance and a valid prescription for RHAPSIDO, and a delay or denial of coverage. Program requires the submission of a prior authorization or an appeal of the coverage denial within the first 90 days of enrollment to remain eligible. Program provides RHAPSIDO for free to eligible patients for up to 12 months, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional limitations may apply. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Please see full Novartis Pharmaceuticals Corporation Privacy Policy and the Mobile Terms of Use.





6/25